ENDPOINTS

FDA lifts hold on Entrada's Duchenne drug after two years

Entrada Therapeutics announced Monday that the FDA lifted the clinical hold on its Duchenne muscular dystrophy drug, and it plans to start a Phase 1b study in the US in 2026. The biotech

Feb 24, 2025 - 17:04
 0
FDA lifts hold on Entrada's Duchenne drug after two years
Entrada Therapeutics announced Monday that the FDA lifted the clinical hold on its Duchenne muscular dystrophy drug, and it plans to start a Phase 1b study in the US in 2026. The biotech
Read More

Tags:

Previous Article

CIO Podcast – Episode 90: AI Use Cases with Barry Stein

Next Article

NASA picks SpaceX rocket to launch asteroid threat hunter NEO Surveyor in 2027

Related Posts

#ASCOGU: Pfizer’s prostate cancer data leak, show promising results in early-stage study

#ASCOGU: Pfizer’s prostate cancer data leak, show promi...

Feb 11, 2025  0

Illumina to lay off about 100 people; Incyte’s new AI partnership

Illumina to lay off about 100 people; Incyte’s new AI p...

Feb 20, 2025  0

Inventiva cuts pipeline, lays off nearly entire research team in bid to get to Phase 3 MASH readout

Inventiva cuts pipeline, lays off nearly entire researc...

Feb 11, 2025  0